MX2009007053A - Inhibidores de poli (adp-ribosa) polimerasa. - Google Patents
Inhibidores de poli (adp-ribosa) polimerasa.Info
- Publication number
- MX2009007053A MX2009007053A MX2009007053A MX2009007053A MX2009007053A MX 2009007053 A MX2009007053 A MX 2009007053A MX 2009007053 A MX2009007053 A MX 2009007053A MX 2009007053 A MX2009007053 A MX 2009007053A MX 2009007053 A MX2009007053 A MX 2009007053A
- Authority
- MX
- Mexico
- Prior art keywords
- adp
- ribose
- polymerase
- inhibitors
- poly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
Abstract
Se describen inhibidores de poli(ADP-ribosa)polimerasa, formas para elaborarlos y métodos para tratar pacientes utilizándolos tal como se describe.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88227006P | 2006-12-28 | 2006-12-28 | |
PCT/US2007/087250 WO2008082887A2 (en) | 2006-12-28 | 2007-12-12 | Inhibitors of poly(adp-ribose)polymerase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009007053A true MX2009007053A (es) | 2009-07-09 |
Family
ID=39154384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009007053A MX2009007053A (es) | 2006-12-28 | 2007-12-12 | Inhibidores de poli (adp-ribosa) polimerasa. |
Country Status (8)
Country | Link |
---|---|
US (1) | US7790721B2 (es) |
EP (1) | EP2114948B1 (es) |
JP (3) | JP5496680B2 (es) |
CN (1) | CN101616919B (es) |
CA (1) | CA2672860C (es) |
ES (1) | ES2506090T3 (es) |
MX (1) | MX2009007053A (es) |
WO (1) | WO2008082887A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5271897B2 (ja) * | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ(ADP−リボース)ポリメラーゼ(PARP)の阻害剤としての、ピロロ[1,2−a]ピラジン−1(2H)−オン及びピロロ[1,2−d][1,2,4]トリアジン−1(2H)−オン誘導体 |
DK2032701T3 (da) | 2006-06-23 | 2014-02-10 | Alethia Biotherapeutics Inc | Polynukleotider og polypeptider, der er inddraget i cancer |
MX336869B (es) | 2008-11-03 | 2016-02-04 | Alethia Biotherapeutics Inc | Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor. |
BRPI0922224A2 (pt) | 2008-12-08 | 2016-08-02 | Vm Pharma Llc | composições de inibidores de proteína tirosina quiinase receptora. |
ES2423668T3 (es) | 2009-05-22 | 2013-09-23 | Abbvie Inc. | Moduladores de receptores 5-HT y métodos de uso de los mismos |
EP2459561A1 (en) * | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
CN103002735B (zh) * | 2010-05-21 | 2015-05-20 | Abbvie公司 | 5-ht受体的调节剂和其使用方法 |
HUE045943T2 (hu) | 2011-03-31 | 2020-02-28 | Adc Therapeutics Sa | Veseasszociált antigén 1 és antigénkötõ fragmensei elleni antitestek |
CN103703002B (zh) * | 2011-07-13 | 2016-05-11 | 参天制药株式会社 | 具有parp抑制活性的新型化合物 |
AU2013209234B2 (en) | 2012-01-09 | 2017-11-09 | Adc Therapeutics Sa | Method for treating breast cancer |
EP2831077B1 (en) * | 2012-03-28 | 2016-04-27 | Merck Patent GmbH | Bicyclic pyrazinone derivatives |
WO2013189905A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Pyrrolopyrazone inhibitors of tankyrase |
US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
US10301271B2 (en) | 2014-09-17 | 2019-05-28 | Purdue Pharma L.P. | Crystalline forms of tyrosine kinase inhibitors and their salts |
BR112018009550A2 (pt) | 2015-11-13 | 2018-11-06 | Mavalon Therapeutics Ltd | derivados de 1,4-benzodiazepinona tricíclica substituída como moduladores alostéricos de receptores de glutamato metabotrópico de grupo ii |
CA3049251A1 (en) | 2017-01-09 | 2018-07-12 | Shuttle Pharmaceuticals, Inc. | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation |
CA3063288A1 (en) * | 2017-05-12 | 2018-11-15 | Mavalon Therapeutics Limited | Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4446323A (en) * | 1983-05-23 | 1984-05-01 | American Home Products Corporation | Tetra- and hexa-hydropyrrolo(1,2-a)quinoxaline and azaquinoxaline derivatives |
DE4228095A1 (de) * | 1992-08-24 | 1994-03-03 | Asta Medica Ag | Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung |
HUT76323A (en) * | 1994-02-11 | 1997-08-28 | Novo Nordisk As | Imidazo[1,2-a]quinoxalinone derivatives, process for their preparation and pharmaceutical compositions containing them |
US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US6635626B1 (en) * | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US7026311B2 (en) * | 2002-01-10 | 2006-04-11 | Abbott Gmbh & Co., Kg | Dibenzodiazepine derivatives, their preparation and use |
AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
ATE540928T1 (de) * | 2002-11-22 | 2012-01-15 | Mitsubishi Tanabe Pharma Corp | Isochinolinverbindungen und ihre medizinische verwendung |
US20040180898A1 (en) * | 2003-03-03 | 2004-09-16 | Bang-Chi Chen | Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines |
JP2005008604A (ja) | 2003-06-23 | 2005-01-13 | Ono Pharmaceut Co Ltd | ピリダジノン誘導体およびその中間体の製造方法 |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
JP5064216B2 (ja) * | 2004-07-16 | 2012-10-31 | プロテオシス・アーゲー | 炎症性疾患用治療剤としての、parp及びsir調節活性を有するムスカリンアンタゴニスト |
US20090238761A1 (en) * | 2005-01-03 | 2009-09-24 | Universita Degli Studi Di Siena | Novel Aryl Piperazine Derivatives With Medical Utility |
WO2006094210A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
EP1798233A1 (en) | 2005-12-19 | 2007-06-20 | Faust Pharmaceuticals | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof |
JP5271897B2 (ja) * | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ(ADP−リボース)ポリメラーゼ(PARP)の阻害剤としての、ピロロ[1,2−a]ピラジン−1(2H)−オン及びピロロ[1,2−d][1,2,4]トリアジン−1(2H)−オン誘導体 |
GB0615809D0 (en) * | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
FR2921927B1 (fr) * | 2007-10-03 | 2012-10-12 | Univ De Montpellier 1 | Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers |
-
2007
- 2007-12-12 WO PCT/US2007/087250 patent/WO2008082887A2/en active Application Filing
- 2007-12-12 EP EP07855102.5A patent/EP2114948B1/en active Active
- 2007-12-12 ES ES07855102.5T patent/ES2506090T3/es active Active
- 2007-12-12 CA CA2672860A patent/CA2672860C/en not_active Expired - Fee Related
- 2007-12-12 MX MX2009007053A patent/MX2009007053A/es active IP Right Grant
- 2007-12-12 JP JP2009544160A patent/JP5496680B2/ja not_active Expired - Fee Related
- 2007-12-12 CN CN2007800518625A patent/CN101616919B/zh not_active Expired - Fee Related
- 2007-12-27 US US11/964,788 patent/US7790721B2/en not_active Expired - Fee Related
-
2014
- 2014-03-04 JP JP2014041488A patent/JP2014129398A/ja active Pending
-
2016
- 2016-04-07 JP JP2016077054A patent/JP2016164175A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
US7790721B2 (en) | 2010-09-07 |
WO2008082887A3 (en) | 2008-12-04 |
JP2016164175A (ja) | 2016-09-08 |
WO2008082887A2 (en) | 2008-07-10 |
US20080161292A1 (en) | 2008-07-03 |
JP5496680B2 (ja) | 2014-05-21 |
JP2014129398A (ja) | 2014-07-10 |
CA2672860A1 (en) | 2008-07-10 |
CN101616919A (zh) | 2009-12-30 |
ES2506090T3 (es) | 2014-10-13 |
CA2672860C (en) | 2013-01-29 |
JP2010514780A (ja) | 2010-05-06 |
EP2114948A2 (en) | 2009-11-11 |
EP2114948B1 (en) | 2014-06-25 |
CN101616919B (zh) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY190838A (en) | Inhibitors of poly(adp-ribose)polymerase | |
MX2009007053A (es) | Inhibidores de poli (adp-ribosa) polimerasa. | |
EP2079500A4 (en) | DEVICES AND METHODS FOR INFUSION | |
WO2009012280A3 (en) | Benzimidazole poly(adp-ribose)polymerase inhibitors | |
ZA201103036B (en) | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | |
BRPI0814941A2 (pt) | Composição de tratamentode semente, e, método de tratamento de semente. | |
WO2009044173A3 (en) | Methods of treating cancer using notch pathway inhibitors | |
MX2022009759A (es) | El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea. | |
TN2012000170A1 (en) | Compositions for treating centrally mediated nausea and vomiting | |
GB0614026D0 (en) | Amplifier Circuits, Methods of Starting and Stopping Amplifier Circuits | |
MX2009009761A (es) | Composiciones y estuches para tratamiento de la influenza. | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
EP2012780A4 (en) | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES AS POTENTE PARP HEMMER | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
EP2165715A4 (en) | THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER | |
MX2009005725A (es) | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
HK1162502A1 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3 | |
MX2009006812A (es) | Moduladores del receptor c3a y metodos de uso de los mismos. | |
WO2008039642A3 (en) | Methods and compounds for treatment of clostridium based infection | |
MX2009003022A (es) | Composiciones y metodos para tratar picaduras de medusa. | |
ZA200901452B (en) | Treatment of vertigo with acetyl-L-leucine | |
WO2008115478A3 (en) | Method of cancer detection and treatment | |
PH12014500538A1 (en) | Methods and compositions for treating leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |